Neurimmune and AstraZeneca collaborate to develop human monoclonal antibody

pharmafile | January 7, 2022 | News story | Medical Communications  

Neurimmune AG announced that it has entered into an exclusive global collaboration and license agreement with Alexion, AstraZeneca Rare Disease group, to develop NI006. This is an investigational human monoclonal antibody specifically targeting misfolded transthyretin.

Neurimmune is a clinical stage biopharmaceutical company, translating human immune memory into antibody therapeutics. Neuroimmune develops drug candidates for CNS and related protein aggregation diseases, including Alzheimer’s disease and Parkinson’s disease.

NI006 is currently being investigated in a Phase Ib clinical study, in ATTR-CM patients conducted in four European countries.

Under the terms of the agreement, Alexion will be granted an exclusive, worldwide license to develop, manufacture, and commercialise Neurimmune’s NI006. Neurimmune will receive an upfront payment of $30 million.

“ATTR-CM is characterised by deposition of misfolded and aggregated transthyretin in the heart. Using our Reverse Translational Medicine technology, we developed a human monoclonal antibody that exclusively targets ATTR to remove amyloid from hearts,” said Jan Grimm, CSO of Neurimmune.

Christoph Hock, CMO of Neurimmune, said: “We are pleased to collaborate with Alexion on this potentially disease-modifying antibody therapy for the treatment of ATTR-CM. Given Alexion’s extensive experience in developing and bringing to market medicines for people with rare diseases, we believe Alexion is uniquely positioned to advance NI006 for patients with this devastating and life-threatening disease.”

The transaction is expected to be finalised, following fulfilment of customary closing conditions, and regulatory clearances.

Lina Adams

Related Content

No items found

Latest content